Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

johnnygogogo Jun. 18 at 7:26 PM

$ARWR $IONS don’t tell Art, but A-roar and I-yawns are within $1B of each other on mkt cap. One has had a ton of recent insider sales and the other is the next Amgen. @skeezbag

3 · Reply

LeftyT Jun. 18 at 4:18 PM

$ARWR and $PRQR will have a strong Q3 IMHO. I'm buying all dips and averaging up on both of these for long term holds based on solid platform driven performance opportunities.

1 · Reply

skeezbag Jun. 18 at 3:01 PM

$ARWR nvda and every momentum fueled semi must be up

0 · Reply

StockingStuffer2832 Jun. 18 at 2:13 PM

$ARWR sane story every day. Pop at the open tank 15-30 minutes later. Been this way for weeks and weeks now.

0 · Reply

BiodegradableBurger Jun. 18 at 2:11 PM

$ARWR L M A O!

0 · Reply

Lolobel Jun. 18 at 1:33 PM

$ARWR nice volume

0 · Reply

CDMO Jun. 18 at 1:31 PM

$ARWR 84 !!!

0 · Reply

Wolfman5960 Jun. 18 at 11:46 AM

$ARWR Arrowhead announced their Summer Series R&D webinar focusing on their cardiometabolic pipeline will be on June 29th at 11:30AM EDT. https://arrowheadpharma.com/en-us/newsroom/arrowhead-pharmaceuticals-host-webinar-its-cardiometabolic ARO-DIMER-PA is on the list so hopefully they'll share some initial data on this.

0 · Reply

NeverFadeTheOracle Jun. 17 at 7:54 PM

$ARWR Clipped out

2 · Reply

NeverFadeTheOracle Jun. 17 at 7:09 PM

$SYRE New Highs and $ARWR $AMRX in reach Eyeing $AXSM

0 · Reply

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Jun 10, 2026, 9:00 AM EDT - 9 days ago

Arrowhead Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 8:10 AM EDT - 16 days ago

Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:30 AM EDT - 17 days ago

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

2026-05-27T11:20:49.000Z - 23 days ago

Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

May 27, 2026, 7:00 AM EDT - 23 days ago

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

2026-05-26T16:29:12.000Z - 24 days ago

Arrowhead presents clinical cardiometabolic data at EAS Congress

May 26, 2026, 10:00 AM EDT - 24 days ago

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

May 20, 2026, 9:00 AM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 13, 2026, 10:00 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 7:00 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals Slides: Corporate presentation

2026-05-13T10:38:55.000Z - 5 weeks ago

Arrowhead price target raised to $46 from $35 at Bernstein

2026-05-08T08:35:40.000Z - 6 weeks ago

Arrowhead price target raised to $90 from $80 at Chardan

2026-05-07T21:01:13.000Z - 6 weeks ago

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Earnings release: Q2 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Quarterly report: Q2 2026

May 7, 2026, 4:01 PM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

2026-05-05T12:17:38.000Z - 6 weeks ago

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

MDGL

May 5, 2026, 8:00 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

MDGL

May 4, 2026, 7:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

2026-05-01T11:47:46.000Z - 7 weeks ago

Arrowhead announces Australian TGA approved Redemplo for FCS

May 1, 2026, 7:30 AM EDT - 7 weeks ago

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

2026-05-01T08:45:41.000Z - 7 weeks ago

Arrowhead initiated with an Overweight at JPMorgan

2026-04-24T10:46:32.000Z - 2 months ago

Arrowhead announces EMA recommended approval of Redemplo

Apr 24, 2026, 6:39 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Apr 21, 2026, 10:04 AM EDT - 2 months ago

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.

2026-04-21T09:10:37.000Z - 2 months ago

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

Apr 20, 2026, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

2026-04-20T15:29:23.000Z - 2 months ago

Arrowhead price target raised to $93 from $81 at BofA

2026-03-29T16:00:33.000Z - 2 months ago

Arrowhead presents long-term efficacy, safety data for plozasiran

Mar 28, 2026, 10:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

2026-03-26T15:20:29.000Z - 3 months ago

Arrowhead price target lowered to $81 from $84 at BofA

IONS

Mar 9, 2026, 2:20 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 11:50 AM EST - 3 months ago

Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

2026-02-06T15:40:15.000Z - 4 months ago

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Feb 5, 2026, 4:30 PM EST - 4 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026

Feb 5, 2026, 4:30 PM EST - 4 months ago

Arrowhead Pharmaceuticals Quarterly report: Q1 2026

Feb 5, 2026, 4:30 PM EST - 4 months ago

Arrowhead Pharmaceuticals Earnings release: Q1 2026

Feb 5, 2026, 4:05 PM EST - 4 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Feb 4, 2026, 6:15 PM EST - 4 months ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT CIEN DAY DVAX OSW

2026-02-04T22:26:13.000Z - 4 months ago

Arrowhead to replace Ciena in S&P 400 at open on 2/9

CIEN

2026-02-04T22:25:49.000Z - 4 months ago

ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9

ADT

2026-01-27T12:45:29.000Z - 5 months ago

Arrowhead doses first patient in ARO-DIMER-PA trial

Jan 27, 2026, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 27, 2026, 7:00 AM EST - 5 months ago

Arrowhead Pharmaceuticals Proxy statement: Proxy Filing

Jan 27, 2026, 7:00 AM EST - 5 months ago

Arrowhead Pharmaceuticals Proxy statement: Proxy Filing

2026-01-22T13:27:58.000Z - 5 months ago

Arrowhead price target raised to $101 from $61 at B. Riley

Jan 20, 2026, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 12, 2026, 10:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 11:05 PM EST - 5 months ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 6, 2026, 6:14 PM EST - 5 months ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 11:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Transcript: Study Update

Jan 6, 2026, 11:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Press release: Study Update

Jan 6, 2026, 11:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Slides: Study Update

Jan 6, 2026, 11:26 AM EST - 5 months ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 5, 2026, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Dec 23, 2025, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 15, 2025, 4:30 PM EST - 6 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 8, 2025, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 8, 2025, 7:00 AM EST - 6 months ago

Arrowhead Pharmaceuticals Slides: Corporate presentation

Dec 4, 2025, 10:00 AM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 1, 2025, 4:00 PM EST - 7 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Nov 25, 2025, 4:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q4 2025

Nov 25, 2025, 4:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Annual report: Q4 2025

Nov 25, 2025, 4:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Earnings release: Q4 2025

Nov 25, 2025, 4:00 PM EST - 7 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 24, 2025, 1:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 24, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Nov 19, 2025, 6:00 AM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 1:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Transcript: Study Result

Nov 18, 2025, 1:30 PM EST - 7 months ago

Arrowhead Pharmaceuticals Press release: Study Result

Nov 18, 2025, 11:52 AM EST - 7 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:21 AM EST - 7 months ago

US FDA approves Arrowhead's genetic disorder drug

Nov 6, 2025, 4:30 PM EST - 8 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 4, 2025, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Oct 21, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 7, 2025, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Sep 11, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 10, 2025, 11:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 9, 2025, 10:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 9:10 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 10 months ago

Arrowhead Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:13 AM EDT - 10 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Aug 27, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 13, 2025, 4:10 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Earnings release: Q3 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Quarterly report: Q3 2025

Aug 7, 2025, 4:01 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 1, 2025, 6:30 AM EDT - 11 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Jul 28, 2025, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Jul 23, 2025, 8:00 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 21, 2025, 4:01 PM EDT - 11 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 9, 2025, 2:00 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

johnnygogogo Jun. 18 at 7:26 PM

$ARWR $IONS don’t tell Art, but A-roar and I-yawns are within $1B of each other on mkt cap. One has had a ton of recent insider sales and the other is the next Amgen. @skeezbag

3 · Reply

LeftyT Jun. 18 at 4:18 PM

$ARWR and $PRQR will have a strong Q3 IMHO. I'm buying all dips and averaging up on both of these for long term holds based on solid platform driven performance opportunities.

1 · Reply

skeezbag Jun. 18 at 3:01 PM

$ARWR nvda and every momentum fueled semi must be up

0 · Reply

StockingStuffer2832 Jun. 18 at 2:13 PM

$ARWR sane story every day. Pop at the open tank 15-30 minutes later. Been this way for weeks and weeks now.

0 · Reply

BiodegradableBurger Jun. 18 at 2:11 PM

$ARWR L M A O!

0 · Reply

Lolobel Jun. 18 at 1:33 PM

$ARWR nice volume

0 · Reply

CDMO Jun. 18 at 1:31 PM

$ARWR 84 !!!

0 · Reply

Wolfman5960 Jun. 18 at 11:46 AM

0 · Reply

NeverFadeTheOracle Jun. 17 at 7:54 PM

$ARWR Clipped out

2 · Reply

NeverFadeTheOracle Jun. 17 at 7:09 PM

$SYRE New Highs and $ARWR $AMRX in reach Eyeing $AXSM

0 · Reply

Olivia_Strickland Jun. 17 at 6:19 PM

$ARWR running hard this session, +7% and still pushing. these gap-and-go moves can absolutely stall at extension. watching to see if it bases at current levels or starts fading into the close. what level you watching here? live tape on the breakout: https://tapeboard.com/research/ARWR?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=arwr-bk-up-tape&utm_term=research

1 · Reply

magross24 Jun. 17 at 6:12 PM

$ARWR good sign it held with rate announcement…

0 · Reply

Jblack500 Jun. 17 at 5:49 PM

$ARWR $HALO arwr new 52 week nice to see..halo backtested breakout of channel

0 · Reply

FUDBusterzz Jun. 17 at 5:25 PM

$ARWR we have some data thingys coming up. Might be more upgrades ahead

0 · Reply

johnnygogogo Jun. 17 at 4:20 PM

$ARWR here’s Mani announcing his new price target (1 of 2)

2 · Reply

CDMO Jun. 17 at 3:52 PM

$ARWR 80? Yes!

1 · Reply

STOCKROCKER8 Jun. 17 at 3:23 PM

$ARWR come on $80

1 · Reply

johnnygogogo Jun. 17 at 1:50 PM

$ARWR Mani to $71 from $61 or $62. Good job Mani. Leerink will never get business from Arrowhead so it’s whatever clown makeup you feel like applying to your model.

3 · Reply

johnnygogogo Jun. 16 at 3:53 PM

$ARWR just want to remind everyone that (today) the market is real and the company is fake.

1 · Reply

johnnygogogo Jun. 15 at 7:49 PM

$ARWR just want to remind everyone that the company is real and the market is fake

1 · Reply

johnnygogogo Jun. 15 at 3:47 PM

$ARWR now trading right around the dark pool number from a few weeks ago (for the special agent / eagle-eyed observers… who don’t believe in coincidence) @skeezbag

0 · Reply

ILUVSPEWINGNONSENSE Jun. 13 at 3:31 PM

$AMGN $ARWR Anyone here know when CVOT data will be released for LP with a little a ? It's going to be a blockbuster!

2 · Reply

Market Cap	11.52B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-0.20%
Debt to Equity Ratio	1.47

Volume	3,863,400
Avg Vol	1,756,210
Day's Range	N/A - N/A
Shares Out	140.86M
Stochastic %K	82%
Beta	1.28
Analysts	Strong Sell
Price Target	$88.77